Literature DB >> 12528146

Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.

Jack R Lichtenstein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12528146     DOI: 10.1002/art.10628

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  8 in total

1.  The use of sildenafil in pediatric Takayasu arteritis.

Authors:  Imad W Uthman; Hala Chaaban
Journal:  Clin Rheumatol       Date:  2005-10-12       Impact factor: 2.980

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 3.  A review of chronic anal fissure management.

Authors:  E E Collins; J N Lund
Journal:  Tech Coloproctol       Date:  2007-08-03       Impact factor: 3.781

Review 4.  Recent achievements in the management of Raynaud's phenomenon.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 5.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

6.  Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Authors:  Zsuzsanna H McMahan; Fredrick M Wigley
Journal:  Int J Clin Rheumtol       Date:  2010

Review 7.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 8.  Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.

Authors:  Sharron H Francis; Jackie D Corbin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.